Cytokinetics (NASDAQ:CYTK) Reaches New 52-Week Low on Analyst Downgrade

Shares of Cytokinetics, Incorporated (NASDAQ:CYTK) hit a new 52-week low during trading on Thursday after Leerink Partners lowered their price target on the stock from $103.00 to $100.00. Leerink Partners currently has an outperform rating on the stock. Cytokinetics traded as low as $57.55 and last traded at $56.60, with a volume of 575,260 shares. The stock had previously closed at $63.60.

Other analysts have also recently issued research reports about the company. Citizens Jmp raised their price objective on Cytokinetics from $105.00 to $110.00 and gave the stock a “market outperform” rating in a research report on Friday, August 7th. JPMorgan Chase & Co. lifted their price objective on shares of Cytokinetics from $97.00 to $103.00 and gave the company an “overweight” rating in a report on Thursday, August 13th. HC Wainwright restated a “buy” rating and set a $140.00 target price on shares of Cytokinetics in a research note on Monday, October 19th. Citigroup reissued a “market outperform” rating on shares of Cytokinetics in a research note on Friday, August 7th. Finally, Needham & Company LLC boosted their target price on shares of Cytokinetics from $102.00 to $112.00 and gave the stock a “buy” rating in a research report on Friday, August 7th. Nineteen investment analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat, Cytokinetics currently has a consensus rating of “Moderate Buy” and a consensus target price of $106.67.

Insider Activity

In related news, EVP Fady Malik sold 3,500 shares of Cytokinetics stock in a transaction dated Tuesday, September 22nd. The shares were sold at an average price of $68.29, for a total transaction of $239,015.00. Following the sale, the executive vice president directly owned 153,902 shares in the company, valued at $10,509,967.58. The trade was a 2.22% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Robert I. Blum sold 97,926 shares of the company’s stock in a transaction on Tuesday, September 15th. The shares were sold at an average price of $69.33, for a total value of $6,789,209.58. Following the sale, the chief executive officer directly owned 385,320 shares of the company’s stock, valued at approximately $26,714,235.60. This represents a 20.26% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last three months, insiders sold 180,926 shares of company stock worth $12,510,340. 2.60% of the stock is owned by insiders.

Cytokinetics News Roundup

Here are the key news stories impacting Cytokinetics this week:

• Positive Sentiment: Cytokinetics reported a third-quarter loss of $1.37 per share, narrower than the $1.43-per-share consensus loss, and revenue of $47.56 million versus expectations of $41.88 million. Revenue rose sharply year over year, and the loss narrowed from $2.55 per share a year earlier. Earnings results
• Positive Sentiment: RBC Capital Markets sees MYQORZO potentially driving a revenue inflection starting in 2027, supporting the longer-term growth case. RBC Capital Markets view
• Positive Sentiment: Analyst sentiment remained supportive: Morgan Stanley initiated a Buy view, while Citigroup raised its target to $105 and Leerink Partners set a new $100 target with an Outperform rating. Morgan Stanley rating Citigroup rating
• Neutral Sentiment: Leerink’s $100 target was reduced from $103, a modest cut that tempers the otherwise positive analyst news, though the firm maintained its Outperform rating. Leerink Partners rating

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently bought and sold shares of the company. Handelsbanken Fonder AB lifted its position in shares of Cytokinetics by 63.8% during the 2nd quarter. Handelsbanken Fonder AB now owns 405,000 shares of the biopharmaceutical company’s stock worth $34,502,000 after buying an additional 157,700 shares during the period. Great Lakes Advisors LLC bought a new stake in Cytokinetics in the second quarter valued at about $1,960,000. Sanders Morris Harris LLC bought a new stake in Cytokinetics in the third quarter valued at approximately $1,549,000. Seven Fleet Capital Management LP lifted its holdings in Cytokinetics by 93.0% during the second quarter. Seven Fleet Capital Management LP now owns 118,240 shares of the biopharmaceutical company’s stock worth $10,073,000 after acquiring an additional 56,971 shares in the last quarter. Finally, Siren L.L.C. acquired a new stake in Cytokinetics during the 1st quarter worth approximately $40,466,000.

Cytokinetics Stock Down 3.3%

The firm has a market capitalization of $6.68 billion, a price-to-earnings ratio of -8.89 and a beta of 0.45. The business’s fifty day moving average is $65.68 and its 200 day moving average is $69.97.

Cytokinetics (NASDAQ:CYTK) last announced its earnings results on Wednesday, November 4th. The biopharmaceutical company reported ($1.37) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($1.43) by $0.06. The firm had revenue of $47.56 million during the quarter, compared to analyst estimates of $41.88 million. During the same period in the prior year, the business posted ($2.55) EPS. The firm’s quarterly revenue was up 2356.5% compared to the same quarter last year. Equities research analysts expect that Cytokinetics, Incorporated will post -5.97 EPS for the current year.

Cytokinetics Company Profile

Cytokinetics, Incorporated is a biopharmaceutical company focused on discovering and developing medicines that target muscle function and contractility. The company applies muscle biology and sarcomere science to develop potential treatments for cardiovascular and neuromuscular diseases, including conditions in which impaired muscle performance contributes to disease progression.

Its leading investigational program is aficamten, a selective cardiac myosin inhibitor being developed for hypertrophic cardiomyopathy and other potential cardiovascular indications.